A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Launched by HOFFMANN-LA ROCHE · Dec 13, 2010
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Locally advanced or metastatic NSCLC with EGFR mutations
- • Measurable disease according to RECIST criteria
- • Adequate hematological, renal and liver function
- Exclusion Criteria:
- • Previous chemotherapy or therapy against EGFR for metastatic disease
- • Symptomatic cerebral metastases
- • Pre-existing disease of the lung parenchyma such as lung fibrosis, lymphangitic carcinomatosis
- • History of another malignancy except for carcinoma in-situ of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis
- • Concomitant use of coumarins
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto, , Portugal
Aveiro, , Portugal
Coimbra, , Portugal
Lisboa, , Portugal
Lisboa, , Portugal
Lisboa, , Portugal
Lisboa, , Portugal
Porto, , Portugal
Vila Nova De Gaia, , Portugal
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials